Reverse repo fee applicable – Tokyo Stock Exchange-listed securities under Nikkei Sangyo Kinzoku (3) (codes 4082–5589), application date May 22, settlement date May 26.

(Note) The reverse repo rate is shown multiplied by the number of securities lending days. The previous day's reverse repo rate and the maximum fee rate are expressed on a per-day basis. For TSE-listed stocks, the excess borrowed shares represent the combined excess from both the Tokyo Stock Exchange and PTS balances. Securities Lending Days Outstanding (Prev. Day) Reverse Repo Rate (¥) Reverse Repo Rate (¥) Max Fee Rate (¥) Lending Price (¥) Excess Borrowed Shares (shares/units) <4082> Daiichi Kigenso Kagaku Kogyo 1 0.1 0.1 4.2

Jiji PressMay 24 21:50 ET

Genepa, Ridge Eye, and others [Emerging Markets Press Release]

Geneva Pharma received approval for a market segment change to the Tokyo Stock Exchange Standard Market. Noile Immune terminated its partnership agreement with Adaptimmune. Ridge Eye acquired SK Collaboration, a company engaged in information provision services, making it a subsidiary, and also made Soken Joho, which handles manufacturing and sales of information processing equipment, a subsidiary of the subsidiary. Matsuya R&D is subject to a tender offer by Omron Healthcare, a company involved in the manufacturing, development, and sale of health and medical devices and services.

Fisco JapanMay 18 18:30 ET

NeuroImmune---Continued to advance its proprietary drug development business and co-development pipeline in Q1.

NeuroImmune BioTech <4893> announced its first-quarter financial results for the fiscal year ending December 2026 (January-March 2026) on the 14th. The company reported business revenue of 0.00 billion yen (compared to 0.02 billion yen in the same period last year), an operating loss of 2.02 billion yen (compared to a loss of 2.41 billion yen), a recurring loss of 1.52 billion yen (compared to a loss of 2.39 billion yen), and a net quarterly loss of 1.53 billion yen (compared to a loss of 2.40 billion yen). The company continued to advance its proprietary drug development business and co-development pipeline based on PRIME technology.

Fisco JapanMay 17 22:40 ET

Noile-Immune Biotech: Quarterly Financial Results Summary for the First Quarter of the Fiscal Year Ending December 2026 (Japanese GAAP, Non-Consolidated)

JPXMay 14 02:30 ET · Announcements

Corporate Action Memo = Announcements as of April 15

(Recording of announcements made by 6:00 PM) ---------------------------------------------------------------------------------------------------- Financial Stocks Symbol

Jiji PressApr 15 05:11 ET

Noile-Immune Biotech: Interim Report

EDINETMar 30 03:28 ET · Announcements